Oncocyte to Announce Third Quarter 2023 Financial Results
Oncocyte Corporation, a precision diagnostics company, will host a conference call and webcast on November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET to discuss its third quarter financial results and recent highlights. Interested parties can access the call via telephone or the company's website.
11/03/2023 - 08:30 AM
Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET
IRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issued the same day, approximately one hour before the conference call.
Interested parties may access the live call via telephone by dialing toll free (888) 550-5422 for both domestic and international callers. Once dialed in ask to be joined to the Oncocyte Corporation call.
The live webcast of the call may be accessed by visiting the “Events & Presentations” section of the Company’s website at https://investors.oncocyte.com . A replay of the webcast will be available on the Company’s website shortly after the conclusion of the call.
About Oncocyte
Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/
VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
Contact:
Stephanie Princesprince@pcgadvisory.com
The conference call and webcast are scheduled for November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET.
The call is to discuss Oncocyte Corporation's third quarter financial results and recent highlights.
Interested parties can access the call via telephone by dialing toll free (888) 550-5422 or through the company's website.
Yes, a replay of the webcast will be available on the company's website shortly after the conclusion of the call.
Oncocyte Corporation
NASDAQ:OCX
OCX Rankings
#5367 Ranked by Stock Gains
OCX Stock Data
Industry
In-Vitro Diagnostic Substance Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, In-Vitro Diagnostic Substance Manufacturing
Country
US
City
Irvine
About OCX
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
